Search Results | Cancer Research | American Association for Cancer Research

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial

Cancer Res (2022) 82 (4_Supplement): GS4-02.

DOI: https://doi.org/10.1158/1538-7445.SABCS21-GS4-02

Published: 15 February 2022

View article

Journal Articles

Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Cancer Res (2022) 82 (4_Supplement): PD8-07.

DOI: https://doi.org/10.1158/1538-7445.SABCS21-PD8-07

Published: 15 February 2022

View article

Journal Articles

Abstract PS4-08: Biomarker analysis of paclitaxel, ganitumab, and metformin (PGM) therapy in the I-SPY2 neoadjuvant clinical trial

Douglas Yee, Paul Haluska, Denise M Wolf, Christina Yau, Amy Wilson, I-SPY2 TRIAL Consortium, Angela DeMichele, Claudine Isaacs, Jane Perlmutter, Joan Venticinque, Hope S Rugo, Richard Schwab, Nola M Hylton, W Fraser Symmans, Michelle E Melisko, Teresa L Helsten, Laura J van't Veer, Donald A Berry, Laura J Esserman

Cancer Res (2021) 81 (4_Supplement): PS4-08.

DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS4-08

Published: 15 February 2021

View article

Journal Articles

Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Cancer Res (2021) 81 (4_Supplement): PD1-10.

DOI: https://doi.org/10.1158/1538-7445.SABCS20-PD1-10

Published: 15 February 2021

View article

Journal Articles

Abstract PS2-07: Outcomes associated with disseminated tumor cells at surgery after neoadjuvant chemotherapy in high-risk early stage breast cancer: The I-SPY SURMOUNT study

Cancer Res (2021) 81 (4_Supplement): PS2-07.

DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS2-07

Published: 15 February 2021

View article

Journal Articles

Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Cancer Res (2020) 80 (16_Supplement): CT011.

DOI: https://doi.org/10.1158/1538-7445.AM2020-CT011

Published: 15 August 2020

View article

Journal Articles

Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial

Wen Li, Natsuko Onishi, David C Newitt, Jessica Gibbs, Lisa J Wilmes, Ella F Jones, Bonnie N Joe, Laura S Sit, Christina Yau, A. Jo Chien, Elissa Price, Kathy S Albain, Theresa Kuritza, Kevin Morley, Judy C Boughey, Kathy Brandt, Sadia Choudhery, Amy S Clark, Mark Rosen, Elizabeth S McDonald, Anthony D Elias, Dulcy Wolverton, Kelly Fountain, David M Euhus, Heather S Han, Bethany Niell, Jennifer Drukteinis, Julie E Lang, Janice Lu, Jane L Meisel, Zaha Mitri, Rita Nanda, Donald W Northfelt, Tara Sanft, Erica Stringer-Reasor, Rebecca K Viscusi, Anne M Wallace, Douglas Yee, Rachel Yung, Smita M Asare, Michelle E Melisko, Jane Perlmutter, Hope S Rugo, Richard Schwab, W. Fraser Symmans, Laura J van't Veer, Donald A Berry, Angela DeMichele, Hiroyuki Abe, Deepa Sheth, Kirsten K Edmiston, Erin D Ellis, Richard Ha, Ralph Wynn, Erin P Crane, Charlotte Dillis, Michael Nelson, An Church, Claudine Isaacs, Qamar J Khan, Karen Y Oh, Neda Jafarian, Dae Hee Bang, Christiane Mullins, Stefanie Woodard, Kathryn W Zamora, Haydee Ojeda-Fornier, Pulin Sheth, Linda Hovanessian-Larsen, Mohammad Eghtedari, Michael Spektor, Marina Giurescu, Mary S Newell, Michael A Cohen, Elise Berman, Constance Lehman, William Smith, Kim Fitzpatrick, Marisa H Borders, Wei Yang, Basak Dogan, Sally Goudreau, Thelma Brown, Laura J Esserman, Nola M Hylton

Cancer Res (2020) 80 (4_Supplement): PD9-04.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-PD9-04

Published: 15 February 2020

View article

Journal Articles

Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer

Cancer Res (2020) 80 (4_Supplement): PD9-05.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-PD9-05

Published: 15 February 2020

View article

Journal Articles

Abstract P3-11-02: Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial

Cancer Res (2020) 80 (4_Supplement): P3-11-02.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-P3-11-02

Published: 15 February 2020

View article

Journal Articles

Abstract P4-10-02: HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial

Denise M Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown-Swigart, Smita M. Asare, Gillian L. Hirst, Laura Sit, Jane Perlmutter, I-SPY 2 TRIAL Consortium, Minetta Liu, John Park, Angela DeMichele, Douglas Yee, Don Berry, Laura Esserman, Emanuel Petricoin, Laura van t' Veer

Cancer Res (2020) 80 (4_Supplement): P4-10-02.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-P4-10-02

Published: 15 February 2020

View article

Journal Articles

Abstract P6-10-06: Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy

Paula R Pohlmann, Christina Yau, Angela DeMichele, Claudine Isaacs, Judy C Boughey, Nola Hylton, Michelle E Melisko, Jane Perlmutter, Hope S Rugo, W. Fraser Symmans, I-SPY 2 TRIAL Consortium, Donald A Berry, Laura Esserman

Cancer Res (2020) 80 (4_Supplement): P6-10-06.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-P6-10-06

Published: 15 February 2020

View article

Journal Articles

Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI

Wen Li, Natsuko Onishi, David C Newitt, Roy Harnish, Ella F Jones, Lisa J Wilmes, Jessica Gibbs, Elissa Price, Bonnie N Joe, A. Jo Chien, Donald A Berry, Judy C Boughey, Kathy S Albain, Amy S Clark, Kirsten K Edmiston, Anthony D Elias, Erin D Ellis, David M Euhus, Heather S Han, Claudine Isaacs, Qamar J Khan, Julie E Lang, Janice Lu, Jane L Meisel, Zaha Mitri, Rita Nanda, Donald W Northfelt, Tara Sanft, Erica Stringer-Reasor, Rebecca K Viscusi, Anne M Wallace, Douglas Yee, Rachel Yung, Michelle E Melisko, Jane Perlmutter, Hope S Rugo, Richard Schwab, W. Fraser Symmans, Laura J van't Veer, Christina Yau, Smita M Asare, Angela DeMichele, Sally Goudreau, Hiroyuki Abe, Deepa Sheth, Dulcy Wolverton, Kelly Fountain, Richard Ha, Ralph Wynn, Erin P Crane, Charlotte Dillis, Theresa Kuritza, Kevin Morley, Michael Nelson, An Church, Bethany Niell, Jennifer Drukteinis, Karen Y Oh, Neda Jafarian, Kathy Brandt, Sadia Choudhery, Dae Hee Bang, Christiane Mullins, Stefanie Woodard, Kathryn W Zamora, Haydee Ojeda-Fornier, Mohammad Eghedari, Pulin Sheth, Linda Hovanessian-Larsen, Mark Rosen, Elizabeth S McDonald, Michael Spektor, Marina Giurescu, Mary S Newell, Michael A Cohen, Elise Berman, Constance Lehman, William Smith, Kim Fitzpatrick, Marisa H Borders, Wei Yang, Basak Dogan, Laura J Esserman, Nola M Hylton

Cancer Res (2020) 80 (4_Supplement): P6-02-01.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-P6-02-01

Published: 15 February 2020

View article

Journal Articles

Abstract P2-12-06: The clinical benefit index: A pilot study integrating treatment efficacy and quality of life in oncology clinical trials

Amrita Basu, Errol J. Philip, Barry Dewitt, Janel Hanmer, Aheli Chattopadhyay, Christina Yau, Smita Asare, Karyn Digiorgio, Ruby Singhrao, Adam Asare, Jane Perlmutter, I-SPY 2 Consortium, Michelle Melisko, Laura Esserman

Cancer Res (2020) 80 (4_Supplement): P2-12-06.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-P2-12-06

Published: 15 February 2020

View article

Journal Articles

Abstract P2-20-02: Site of recurrence after neoadjuvant therapy: Clues to biology and impact on endpoints

Cancer Res (2020) 80 (4_Supplement): P2-20-02.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-P2-20-02

Published: 15 February 2020

View article

Journal Articles

Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL

Cancer Res (2020) 80 (4_Supplement): P3-09-02.

DOI: https://doi.org/10.1158/1538-7445.SABCS19-P3-09-02

Published: 15 February 2020

View article

Journal Articles

Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL

Cancer Res (2019) 79 (13_Supplement): CT136.

DOI: https://doi.org/10.1158/1538-7445.AM2019-CT136

Published: 01 July 2019

View article

Journal Articles

Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Cancer Res (2016) 76 (14_Supplement): CT106.

DOI: https://doi.org/10.1158/1538-7445.AM2016-CT106

Published: 15 July 2016

View article

Journal Articles

Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Cancer Res (2016) 76 (14_Supplement): CT042.

DOI: https://doi.org/10.1158/1538-7445.AM2016-CT042

Published: 15 July 2016

View article

Journal Articles

Abstract P3-06-37: I-SPY 2 qualifying biomarker evaluation (QBE): The challenge and opportunity for interrogating predicted pathways in an adaptive design biomarker rich trial

Christina Yau, Denise Wolf, Ashish Sanil, Laura van 't Veer, Emanuel F Petricoin, Meredith Buxton, Joe Gray, Angela DeMichele, Mike Hogarth, Nola Hylton, Jane Perlmutter, Melissa Paoloni, Fraser Symmans, Doug Yee, Don Berry, Laura Esserman

Cancer Res (2015) 75 (9_Supplement): P3-06-37.

DOI: https://doi.org/10.1158/1538-7445.SABCS14-P3-06-37

Published: 01 May 2015

View article

Journal Articles

Cancer Research Advocacy: Past, Present, and Future

Jane Perlmutter, Shannon K. Bell, Gwen Darien

Cancer Res (2013) 73 (15): 4611–4615.

DOI: https://doi.org/10.1158/0008-5472.CAN-12-4553-T

Published: 31 July 2013

View article

NARROW

Abstract GS4-02: Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial

Abstract PD8-07: Evaluation of Tucatinib + (Paclitaxel + Pertuzumab + Trastuzumab) followed by AC in high-risk HER2 positive (HER2+) stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Abstract PS4-08: Biomarker analysis of paclitaxel, ganitumab, and metformin (PGM) therapy in the I-SPY2 neoadjuvant clinical trial

Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Abstract PS2-07: Outcomes associated with disseminated tumor cells at surgery after neoadjuvant chemotherapy in high-risk early stage breast cancer: The I-SPY SURMOUNT study

Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

Abstract PD9-04: Breast cancer subtype specific association of pCR with MRI assessed tumor volume progression during NAC in the I-SPY 2 trial

Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer

Abstract P3-11-02: Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial

Abstract P4-10-02: HER2 signaling, ER, and proliferation biomarkers predict response to multiple HER2-targeted agents/combinations plus standard neoadjuvant therapy in the I-SPY 2 trial

Abstract P6-10-06: Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy

Abstract P6-02-01: The effect of background parenchymal enhancement on the predictive performance of functional tumor volume measured in MRI

Abstract P2-12-06: The clinical benefit index: A pilot study integrating treatment efficacy and quality of life in oncology clinical trials

Abstract P2-20-02: Site of recurrence after neoadjuvant therapy: Clues to biology and impact on endpoints

Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL

Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL

Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

Abstract P3-06-37: I-SPY 2 qualifying biomarker evaluation (QBE): The challenge and opportunity for interrogating predicted pathways in an adaptive design biomarker rich trial

Cancer Research Advocacy: Past, Present, and Future

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only